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Abstract: We aimed to explore the differences in the whole transcriptome of peripheral blood mononu-
clear cells between elderly individuals with and without type 2 diabetes (T2D). We conducted a
microarray-based transcriptome analysis of 19 individuals with T2D and 15 without. Differentially
expressed genes according to linear models were submitted to the Ingenuity Pathway Analysis
system to conduct a functional enrichment analysis. We established that diseases, biological func-
tions, and canonical signaling pathways were significantly associated with T2D patients when their
logarithms of Benjamini–Hochberg-adjusted p-value were >1.30 and their absolute z-scores were
>2.0 (≥2.0 meant “upregulation” and ≤−2.0 “downregulation”). Cancer signaling pathways were
the most upregulated ones in T2D (z-score = 2.63, −log(p-value) = 32.3; 88.5% (n = 906) of the total
differentially expressed genes located in these pathways). In particular, integrin (z-score = 2.52,
−log(p-value) = 2.03) and paxillin (z-score = 2.33, −log(p-value) = 1.46) signaling pathways were
predicted to be upregulated, whereas the Rho guanosine diphosphate (Rho-GDP) dissociation in-
hibitor signaling pathway was predicted to be downregulated in T2D individuals (z-score = −2.14,
−log(p-value) = 2.41). Our results suggest that, at transcriptional expression level, elderly individuals
with T2D present an increased activation of signaling pathways related to neoplastic processes,
T-cell activation and migration, and inflammation.
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1. Introduction
Type 2 diabetes (T2D) is a metabolic disorder characterized by chronic insulin re-
sistance and subsequent hyperglycemia. It is a major risk factor for fatal and non-fatal
cardiovascular disease [1], neurodegeneration [2], and cancer [3]. Several inter-related
mechanisms, including oxidative stress, inflammation, and dysregulation of cell dynamics,
have been proposed as the main links between T2D and chronic disease [4,5]. Establishing
these mechanisms could contribute to better understanding of T2D evolution and the
treatment of its complications. Omics technologies, including transcriptomics, proteomics,
and metabolomics, have emerged as promising tools in this field [6]. Transcriptomics,
in particular, help to identify molecular networks impaired in T2D [7]. Nevertheless,
the relevant tissues are often unavailable and gene expression among tissues is relatively
variable [8]. To overcome such limitations, the use of peripheral blood mononuclear cells
(PBMC) has been extensively proposed in the literature [9]. They are circulating immune
cells (T and B lymphocytes, natural killers, and monocytes) that together express up to
80% of the encoded human genome [10] and play a key role in the inflammatory processes
involved in the physiopathology of T2D [11] and its complications [12]. In the current
work, we hypothesized that the whole transcriptome of PBMC would not only reflect the
pathophysiology of T2D, but also elucidate molecular dysregulations potentially related to
the onset of T2D-related complications.
The aim of the present work was to comprehensively analyze the transcriptome of
PBMC from individuals with and without T2D, and subsequently conduct a functional en-
richment analysis to determine the association between T2D and the activation of diseases,
biological functions, and canonical signaling pathways.
2. Experimental Section
2.1. Study Design and Participants
This research followed a baseline, cross-sectional study design and included a subset of
34 participants from the PREDIMED (Prevención con Dieta Mediterránea) study, a clinical
trial aimed at assessing the effectiveness of the traditional Mediterranean diet on the
primary prevention of cardiovascular disease. Between June 2007 and October 2008,
subjects of the current study (n = 34) were randomly selected from a total of 584 recruited at
the Instituto Hospital del Mar de Investigaciones Médicas (Barcelona) PREDIMED center.
They were community-dwelling men (55–80 years) and women (60–80 years) free from
cardiovascular disease at enrollment but presenting either T2D or >3 of the following risk
factors: current smoking, hypertension, high levels of low-density lipoprotein cholesterol,
low concentrations of high-density lipoprotein cholesterol, overweight/obesity, or a family
history of premature coronary heart disease. They were then grouped according to whether
they presented T2D (n = 19) or not (non-T2D, n = 15) at baseline. T2D was defined by clinical
diagnosis or use of antidiabetic medication [13,14]. At the time of recruitment participants
with T2D received both or either antidiabetic medications (i.e., oral or insulin) and/or
lifestyle-based management programs for blood glucose control. A flowchart showing the
participants included in the current substudy, and the transcriptome functional algorithm
analysis followed, is depicted in Figure 1. The study protocol complied with the Declaration
of Helsinki, was approved by local institutional review boards, and was registered under
the International Standard Randomized Controlled Trial Number ISRCTN35739639 (http:
//www.isrctn.com/ISRCTN35739639). All participants provided written informed consent
before joining the trial. Full details of the study design, inclusion and exclusion criteria,
and dietary intervention have been published elsewhere [14,15].
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 Figure 1. Participant and data analysis flowchart followed in the current study. Abbreviations: BH-P,
Benjamini–Hochberg-adjusted p value; DEGs, differentially expressed genes; IMIM, Hospital del Mar
Research Institute; IPA, Ingenuity Pathway Analysis; non-T2D, non-type 2 diabetes; PBMC, peripheral
blood mononuclear cells; PREDIMED, Prevención con Dieta Mediterránea; T2D, type 2 diabetes.
2.2. Biosample Collection and Measurements
Blood samples were collected after an overnight fast, aliquoted, coded, and either
used for biochemical measurements within the first 12 h or frozen at −80 ◦C until microar-
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ray experiments. Biochemical determinations, including serum glucose and lipid profile,
were performed by standard methods [16]. Trained personnel performed the anthropomet-
ric and blood pressure measurements. All participants were required to complete validated
questionnaires to record disease history and medication use [15].
2.3. Microarray Experiments
Blood sample processing, RNA extraction, and microarray experiment procedures
were performed as described by Castañer et al. [16]. In brief, mononuclear cells were iso-
lated from peripheral blood with cell preparation tubes (Becton Dickinson, Franklin Lakes,
NJ, USA) combining differential centrifugations and buffer washings, resuspended in Ul-
traspec RNA Isolation Reagent (Bioteck Laboratories, Hyderabad, Telangana), and finally
stored at –80 ◦C until RNA isolation. Once isolated, RNA was assessed for concentration
and purity with UV spectroscopy (A260) (NanoDrop ND-1000; NanoDrop Technologies),
and for integrity using microcapillary gel electrophoresis (Bioanalyzer, NanoChip; Agilent
Technologies). Gene expression profiling was performed with the customized GeneChip™
Human Genome U133A 2.0 array (Thermofishet Scientific), a commercial microarray plat-
form that analyzes the expression level of 18,400 transcripts and variants, including 14,500
well-characterized human genes. Data from the current microarray were recorded in the
Gene Expression Omnibus repository under the GSE28358 access register and were validated
by quantitative real-time polymerase chain reaction, as reported by Castañer et al. [16].
All microarray experiments, and the subsequent transcriptome data processing and analy-
ses, were performed at the Príncipe Felipe Research Centre, Valencia, Spain.
2.4. Bioinformatic Analyses
We included all 22,277 probe sets represented in the array in the comparison analyses
(Figure 1). The raw signal intensities from microarray experiments were background cor-
rected, log2 transformed, and then quantile-normalized using Robust Multi-array Average
methodology [17]. Subsequently, a principal component analysis and clustering plots were
conducted to assess data distribution. In order to identify differentially expressed genes
between T2D and non-T2D, linear models were conducted with the Limma R/Bioconductor
software package [18]. In this way, a moderated t-statistic (t), p value, and log2-fold changes
(log2-FC) were calculated for each gene. Genes were considered differently expressed when
they presented absolute t-statistics ≥ 2.0 and p values ≤ 0.05. All the statistical procedures
included in this stage were performed using the computing environment R version 2.15.1
(R Development Core Team, 2012).
2.5. Functional Enrichment Analysis
Functional enrichment analysis, including the prediction of diseases, biological func-
tions, and signaling canonical pathways associated with T2D, was performed using Inge-
nuity Pathway Analysis software (IPA; Qiagen, Redwood City, CA, USA) [19]. An input
file containing the differentially expressed genes, moderate t-statistics, and P and log2-FC
values was loaded into the software. The core-expression analysis function, with the “In-
genuity Knowledge Base (Genes only)” as reference set, was then applied. The statistical
significance and direction of activation for each disease, biological function, and signal-
ing canonical pathway were determined using two metrics: the z-score and the adjusted
p value. The z-score is a statistical measure that provides predictions about whether a
biological process is upregulated (positive z-score) or downregulated (negative z-score).
The p value, according to the right-tailed Fisher’s exact test, reflects the likelihood of the
association between a set of genes and a determined biological process being significant.
Furthermore, to control for a false discovery rate among biological process modulations,
the software provides an adjustment of raw p values through the Benjamini–Hochberg (BH)
procedure. In the current work, we considered that a disease, biological function, or canon-
ical pathway was significantly associated with T2D when it showed both a z-score ≥ 2.0
and a BH-adjusted p value ≤ 0.05 (−log(BH-P) ≥ 1.30) [19].
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2.6. Sample Size and Power Analysis
We estimated that a total sample of 34 participants allowed ≥80% of power to detect
at least 5% of true differentially expressed genes between non-T2D and T2D conditions.
Calculations were based on the algorithm proposed by Lin et al. [20], assuming a 95%
probability of detecting such power and proportion of true differentially expressed genes,
a false discovery rate level of 0.05, and log2-FC ≥ 2.0
2.7. Analysis of Anthropometric and Clinical Data
The Kolmogorov–Smirnov test and normal probability plots were used to determine
the distribution of anthropometric and clinical data. Variables with a non-normal distri-
bution were log-transformed prior to analysis. Differences in continuous and categorical
variables between T2D and non-T2D groups were assessed by t-tests and chi-squared tests,
respectively. Statistical analysis of anthropometric and clinical data was conducted with
the SPSS 22.0 software (IBM SPSS Statistics for Windows. Armonk, NY, USA: IBM Corp.).
A p ≤ 0.05 value was considered to be statistically significant in all tests.
3. Results
3.1. Participants’ Characteristics
The characteristics of the participants are presented in Table 1. As expected, T2D
individuals presented higher serum glucose levels (+48 mg/dL) and greater use of oral
antidiabetics and insulin. In addition, the T2D group had 45.9% less hypercholesterolemia
and 21.4% fewer smokers in comparison with non-T2D.




(n = 15) p
Age, years 65 ± 6 63 ± 4 0.37
Female, n (%) 11 (57.9) 8 (53.3) 0.79
Weight, kg 81.0 ± 10.2 75.2 ± 14.3 0.18
BMI, kg/m2 30.1 ± 3.10 28.5 ± 4.35 0.22
Serum glucose, mg/dL 151 ± 55.2 103 ± 20.6 <0.01
Tobacco use, n (%) 0.02
Regular smoker 1 (5.30) 4 (26.7)
Former smoker (>1y) 4 (21.1) 7 (46.7)
Never smoker 14 (73.7) 4 (26.7)
Hypertension, n (%) 13 (68.4) 12 (80.0) 0.70
Hypercholesterolemia, n (%) 9 (47.4) 14 (93.3) 0.01
Medication use, n (%)
Cardiovascular drugs 2 (11.1) 1 (7.10) 0.70
Antihypertensive 13 (68.4) 9 (60.0) 0.72
Hypocholesterolemic 6 (31.6) 5 (33.3) 0.91
Oral antidiabetics 13 (68.4) 0.00 <0.01
Insulin 1 (5.26) 0.00 <0.01
Data are shown as mean ± standard deviation or n (%), as appropriate. Differences between groups were assessed
by t-tests and chi-square test for continuous and categoric variables, respectively.
3.2. Microarray Gene Expression and Functional Enrichment Analysis
We found 1024 differentially expressed genes between T2D and non-T2D individuals
(569 were upregulated and 455 downregulated). Gene expression linked to 11 diseases and
biological functions was predicted to be activated in T2D patients (Figure 2a,b).
Specifically, cancer (z-score = 2.63, −log(BH-P) = 32.3), cellular movement
(z-score = 3.01, −log(BH-P) = 19.4), gene expression (z-score = 2.45, −log(BH-P) = 8.88),
inflammatory response (z-score = 2.37, −log(BH-P) = 8.03), cell-to-cell signaling and in-
teraction (z-score = 3.47, −log(BH-P) = 7.36), cell morphology (z-score = 2.06, −log(BH-P)
= 6.69), and cellular function and maintenance (z-score = 2.66, −log(BH-P) = 5.17) were
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predicted to be upregulated. In contrast, cellular development (z-score = −2.17, −log(BH-
P) = 14.2), hematological system development and function (z-score = −3.55, −log(BH-
P) = 10.0), cell death and survival (z-score = −2.87, −log(BH-P) = 8.81), and connective
tissue disorders (z-score = −2.45, −log(BH-P) = 7.24) were predicted to be downregulated.
According to the number of genes involved (n = 906) and the overlapping percentage
(88.5%) of all differentially expressed genes, cancer signaling was the most activated in
T2D patients (Figure 2c).




Figure 2. Diseases and biological functions predicted to be modulated in elderly individuals with T2D (a,b), and the num-
ber of genes involved in each of them (c). Significant modulations were defined by -logarithm of Benjamini–Hochberg-
adjusted p value (−log(BH-P)) ≥ 1.30 (a) and an absolute z-score ≥ 2.0 (b) (vertical dashed lines, where appropriate). 
Specifically, cancer (z-score = 2.63, −log(BH-P) = 32.3), cellular movement (z-score = 
3.01, −log(BH-P) = 19.4), gene expression (z-score = 2.45, −log(BH-P) = 8.88), inflammatory 
response (z-score = 2.37, −log(BH-P) = 8.03), cell-to-cell signaling and interaction (z-score 
= 3.47, −log(BH-P) = 7.36), cell morphology (z-score = 2.06, −log(BH-P) = 6.69), and cellular 
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Figure 2. Diseases and biological functions predicted to be modulated in elderly individuals with T2D (a,b), and the number
of genes involved in each of them (c). Significant modulations were defined by -logarithm of Benjamini–Hochberg-adjusted
p value (−log(BH-P)) ≥ 1.30 (a) and an absolute z-score ≥ 2.0 (b) (vertical dashed lines, where appropriate).
The Ingenuity athway Analysis (IPA) system also predicted the activation of three
signaling canonical pathways in T2D. Integrin (z-score = 2.52, −log(BH-P) = 2.03; genes:
18 upregulated, 4 downregulated) and paxillin (z-score = 2.33, −log(BH-P) = 1.46; genes:
11 upregulated, 1 downregulated) signaling pathways were predicted to be upregulated,
whereas the Rho guanosine diphosphate ssociation inhibitor (RhoGDI)signaling pathway
was predicted to be downregulated in T2D (z-score = −2.14, −log(BH-P) = 2.41; genes:
16 upregulated, 5 downregulated) (Figure 3).
Distribution of gene expression changes among these signaling pathways is shown
in Figure 4.
According to the IPA, the upregulation of integrin and paxillin signaling pathways,
and the downregulation of RhoGDI signaling pathway, in T2D would lead to the activation
of cytoskeletal organization, rearrangement and reorganization, cell activation, adhesion,
mobility and polarity, lamellipodia and filopodia formation, and actin polymerization and
linkage, and the inhibition of actin stabilization (Figure 5).
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Figure 3. Canonical signaling pathways predicted to be modulated in elderly individuals with T2D
(a,b), and number of genes modulated in each of them (c). Significant modulations were defined
by −logarithm of Benjamini–Hochberg-adjusted p value (−log(BH-P)) ≥ 1.30 (a) and an absolute
z-score ≥ 2.0 (b) (vertical dashed lines, where appropriate).
In the current study, we conducted a microarray-based transcriptome analysis in
elderly individuals with and without T2D, and identified diseases, biological functions,
and canonical pathways differentially expressed in T2D. We found that cancer signaling and
biological functions, and canonical pathways related to cell dynamics, were upregulated in
T2D patients.
T2D has been related with an increased risk of developing a wide set of malignan-
cies [3,21,22]. In addition, a large amount of robust and unbiased epidemiological and
clinical evidence suggests that it is associated with not only an increased risk for cancer
incidence and mortality [3,23,24], but also several cancer types including breast, colorectum,
intrahepatic cholangiocarcinoma, and endometrium. Such findings concur with our results,
which indicate that an upregulation of cancer disease signaling is positively linked with
T2D and that, compared with non-T2D, T2D individuals could have an increased risk of
initiating neoplastic processes.
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Figure 4. Exclusive and common genes downregulated (bold) and upregulated (gray) among inte-
grin, paxillin, and Rho guanosine diphosphate dissociation inhibitor (RhoGDI) signaling pathways
predicted to be modulated in elderly individuals with T2D. MYLK, myosin light chain kinase;
ACTN1, actinin alpha 1; ACTA2, actin alpha 2; AKT3, AKT serine/threonine kinase 3; ARF6, ADP
ribosylation factor 6; ARHGAP6, Rho GTPase activating protein 6; ARHGEF2, Rho/Rac guanine
nucleotide exchange factor 2; CDC42, cell division cycle 42; CDH6, cad-herin 6; CDH15, cadherin 15;
CTNN, beta catenin; DLC1, DLC1 Rho GTPase activating protein; GNA11, G protein subunit alpha 11;
GNAZ, G protein subunit alpha z; GNAL, G protein subunit alpha L; GNB5, G protein subunit beta 5;
GNG11, G protein subunit gamma 11; ITGB3, integrin subunit beta 3; ITGB5, integrin subunit alpha
5; ITGA2B, in-tegrin subunit alpha 2b; ITGB5, integrin subunit beta 5; LIMS1, LIM zinc finger domain
containing 1; MAPK13, mitogen-activated protein kinase 9; MAPK13, mitogen-activated protein
kinase 13; MYL4, myosin light chain 4; MYL9, myosin light chain 9; PTEN, phos-phatase and tensin
homolog; WIPF1, WAS/WASL interacting protein family member 1; PARVB, parvin beta; PPP1R12A,
protein phosphatase 1 regulatory subunit 12A; RND1, Rho family GTPase 1; RHOT1, ras homolog
family member T1; RHOBTB1, Rho related BTB domain co taining 1; SRC, SRC proto-oncogene,
on-receptor tyrosine kinase; VCL, vinculin; WASF1, WASP family member 1.
Obesity and the use of glucose-lowering m dications, tw T2D-as ociated conditions,
have been shown to be relevant modulators of the transcri tome in PBMC [25,26]. Obesity
is strongly associated with g ea er esophageal, colorectal, liver, pancreatic, postmenopausal
breast, endom trial, ren l, gast ic cardia, gallbladder, and ovary cancer risk [27,28]. Re-
garding antidiabetic medications, epidemiological studies suggest that whereas metformin
could act as antineoplastic agent, therapies increasing circulating levels of insulin (i.e., sul-
fonylureas and exogenous insulin) could be related to higher cancer risk [29]. On the other
side, regarding the signaling effects of antidiabetic medications, conflicting data have been
published suggesting that, although their use could potentially enhance proliferation of
premalignant or malignant cells, it is extremely unlikely they introduce malignancy [30].
All these conditions have been proposed as mediators of the relationship between T2D
and cancer development [31], as well as other factors such as oxidative stress, chronic
inflammation, and impaired levels of sex hormones [31–33].
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Obesity and the use of glucose-lowering medications, two T2D-associated condi-
tions, have been shown to be relevant modulators of the transcriptome in PBMC [25,26]. 
Obesity is strongly associated with greater esophageal, colorectal, liver, pancreatic, post-
menopausal breast, endometrial, renal, gastric cardia, gallbladder, and ovary cancer risk 
[27,28]. Regarding antidiabetic medications, epidemiological studies suggest that whereas 
metformin could act as antineoplastic agent, therapies increasing circulating levels of in-
sulin (i.e., sulfonylureas and exogenous insulin) could be related to higher cancer risk [29]. 
On the other side, regarding the signaling effects of antidiabetic medications, conflicting 
data have been published suggesting that, although their use could potentially enhance 
Figure 5. Predicted relationship between expressed and regulated genes within integrin, paxillin, and RhoGDI signaling
pathways, and the consequent activation of diseases and biological functions in elderly individuals with T2D. The figure
was adapted from the corresponding indi al canonical signaling pathways generated by the Ingenuity Pathway
Analysis system. ARF6, ADP-ribosylation factor 6; ARH, low density lipoprotein receptor adaptor protein 1; CDC42,
Cell division control protein 42 homolog; ECM, extracellular matrix; ERM, ezrin/radixin/moesin; FAK, focal adhesion
kinase; GEF, guanine nucleotide exchange factor; GIT2, G protein-cou led receptor kinase-interactor 2 isoform 4; GPCR, G
protein-coupled receptors; GTP, guanosine triphosphate; ILK, Integrin-linked protein kinase; LIMK, lim kinase; MLCK,
Myosin light-chain kinase; MRLC, myosin regulatory light chain; PAK; P21 activated kinase; PXN, paxillin; Rho GAP, Rho
GTPase-activating proteins; VCL, vinculin.4. Discussion.
Our results showing that PBMC transcriptome could be a suitable model to unravel
the relationship between T2D and cancer a consist nt with others previously reported
in literature. In a recent study conducted by Calimlioglu and colleagues (2015), transcrip-
tomics data from different tissues including beta-cells, pancreatic islets, arterial tissue,
PBMC, liver, and skeletal muscle of 228 samples were integrated with protein–protein
interaction data and genome-scale metabolic models to unravel the molecular and tissue-
specific biomarker signatures of T2D [34]. Interestingly, authors found that with exception
of beta cells and arterial tissues, cancer signaling pathways were upregulated in all tissues.
Integrin, paxillin, and RhoGDI signal g pathways are intimately inter-related and
involved in c ll dynamic [35]. Integrins, which mediate cell adhesion and the trans-
duction of external signals to the actin cytoskeleton [36], have been shown to contribute
to cancer progression and drive the therapeutic resistance of some malignancies [37,38].
Paxillin is a regulator of cytoskeleton structure involved in cell attachment, spreading,
and migration [39], and is known to acquire gain-of-function mutations associated with the
progression of many tumors such as colorectal and pancreatic ones [40]. Finally, RhoGDI
dissociation inhibitor proteins mod late Rho-g anosine triphosphatas s (involved in the
regulation of cell adhesio , spreading, migration, polarity, survival, and division) [35].
The underexpression of these proteins promotes cell migration [41] and has been found in
colorectal [42] and pancreatic cancers [43]. According to our findings, the upregulation of
integrin and paxillin, and the downregulation of RhoGDP dissociation inhibitor signaling
pathways, in individuals with T2D could be associated with the promotion of biological
processes involved in cell activation and migration (e.g., cell movement and morphology
and cell-to-cell signaling and interaction) and greater inflammatory responses. Our results
agree with previous evidence indicating that diabetes and chronic hyperglycemia are linked
to the upregulation of integrin and paxillin pathways and the downregulation of RhoGDP
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dissociation inhibitor responses [44–46] and the exacerbated T-cell activation and chronic
low-grade inflammation present in T2D and its complications [47,48].
Our study has some limitations. First, its design was cross-sectional, which only
allowed associations between T2D and differences in transcriptome to be established.
Our conclusions and their clinical implications regarding cancer should, therefore, be cor-
roborated in further studies in humans. Second, it had a relatively small sample size,
which may have limited our statistical power. In order to counteract this limitation and
add robustness to our results, we employed systematic bioinformatic procedures and
functional enrichment analyses, in addition to adjusting for multiple comparisons. Finally,
the presence of other cardiovascular risk factors beyond T2D complicates the extrapolation
of our conclusions to other populations.
4. Conclusions
In summary, T2D was associated with the upregulation of pathways related to cancer
signaling, T-cell activation and migration, and inflammation. Our findings provide, from a
transcriptomic point of view, insights concerning T2D pathophysiology and complications
in a group of elderly adults at high cardiovascular risk. The modulation of present signaling
pathways would be pharmacological targets in the primary prevention of development of
neoplastic processes under T2D condition.
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